Ticker

JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025.

Financial HighlightsRevenue reached RMB1,729.4 millionGross profit amounted to RMB655.6 millionGross profit margin recorded 37.9%, a YOY increase of 3.3 pp Net profit recorded RMB269.3 million, a YOY increase 21.3%Adjusted non-IFRS net profit recorded RMB335.3 million, a YOY increase of nearly 6.6% SHANGHAI, March 30, 2026 /PRNewswire/ -- On March 30, 2026, Viva Biotech Holdings ("Viva Biotech", "the Group" or "the…

INCHEON, South Korea--(BUSINESS WIRE)--Samsung Biologics Labor Union secured a strike mandate, warning that governance failures and rigid management pose CDMO supply chain risks.

SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has also been recognized for excellence across multiple categories for "Large CDMO Biologic", including "Best Scaling Support", "Best…

Reinforcing long-term commitment to embedding sustainability across operations and partnerships Continuing to support clients in delivering high-quality, life-saving medicines to patients worldwide INCHEON, South Korea, March 26, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), received recognition at the 2026 CDMO Leadership Awards…